阿帕替尼联合肝动脉化疗栓塞治疗中晚期肝癌的临床疗效分析  

Clinical Efficacy of Apatinib Combined with Hepatic Arterial Chemoembolization in the Treatment of Advanced Liver Cancer

作　　者：孙志强[1] 姜成毅 陈健[2] SUN Zhiqiang;JIANG Chengyi;CHEN Jian(Department of Comprehensive Surgery,Jilin Cancer Hospital,Changchun,Jilin Province,130000 China;Depart-ment of Interventional,Jilin Cancer Hospital,Changchun,Jilin Province,130000 China)

机构地区：[1]吉林省肿瘤医院综合外科,吉林长春130000 [2]吉林省肿瘤医院介入科,吉林长春130000

出　　处：《中外医疗》2023年第21期134-137,共4页China & Foreign Medical Treatment

基　　金：吉林省卫生健康科技能力提升项目(2021LC132);吉林省科技发展计划项目(20190303168SF)。

摘　　要：目的 探究在中晚期肝癌患者中采用阿帕替尼联合肝动脉化疗栓塞治疗的效果。方法 方便选取2022年1月—2023年4月吉林省肿瘤医院收治的中晚期肝癌患者82例为研究对象,根据随机数表法分为对照组(41例,肝动脉化疗栓塞治疗)与观察组(41例,阿帕替尼联合肝动脉化疗栓塞治疗),对比两组疗效。结果观察组患者治疗有效率为92.68%高于对照组的73.17%,差异有统计学意义(χ^(2)=5.513,P<0.05)。治疗前,两组血清甲胎蛋白、癌胚抗原、血管内皮生长因子水平对比,差异无统计学意义(P>0.05)。治疗后,两组甲胎蛋白、癌胚抗原、血管内皮生长因子水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。结论 在中晚期肝癌患者中运用阿帕替尼联合肝动脉化疗栓塞治疗安全性和有效性俱佳,能控制肝癌血清标志物发展,调节患者肝功能水平。Objective To explore the efficacy of apatinib combined with hepatic arterial chemoembolization in patients with advanced liver cancer.Methods 82 patients with advanced liver cancer admitted to Jilin Provincial Cancer Hospital from January 2022 to April 2023 were conveniently selected as the study subjects.They were randomly divided into a control group(41 cases,treated with hepatic artery chemoembolization) and an observation group(41 cases,treated with apatinib combined with hepatic artery chemoembolization) based on the random number table method,and the therapeutic effects of the two groups were compared.Results The effective rate of treatment in the observation group was 92.68%,which was higher than 73.17% in the control group,the difference was statistically significant(χ^(2)=5.513,P<0.05).Before treatment,there was no statistically significant difference in the levels of serum AFP,CEA,and VEGF between the two groups(P>0.05).After treatment,the levels of AFP,CEA,and VEGF in the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P<0.05).Conclusion Apatinib combined with hepatic arterial chemoembolization is safe and effective in patients with advanced liver cancer,which can control the development of serum markers of liver cancer and regulate the level of liver function in patients.

关 键 词：中晚期肝癌 阿帕替尼 肝动脉化疗栓塞 安全性 疗效 

分 类 号：R4[医药卫生—临床医学]